Wedbush lowered the firm’s price target on Dianthus to $36 from $38 and keeps an Outperform rating on the shares. Most importantly in the company’s Q2 results, it was announced all development timelines remain on track, the analyst tells investors. The firm’s DNTH103 estimates remain unchanged and assume the earliest potential launch in FY28. The firm is also increasing its research and development expense ramp from FY24 forward to reflect the accelerating clinical trial efforts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
- Dianthus initiated with an Outperform at Baird
- Two new option listings on July 9th
- Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
- Dianthus initiated with an Overweight at Cantor Fitzgerald